Table 2 Clinical features of patients with ERBB2 somatic mutations or ERBB2 amplification only in Geneplus cohort
From: Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
Characteristics | ERBB2 oncogenic mutationa (n = 474) | ERBB2 amplification only (n = 175) | P value |
---|---|---|---|
Age, years | Â | Â | <0.01 |
 Mean (SD) | 53.6 (12.8) | 63.0 (9.5) |  |
 Median (min-max) | 54 (21-83) | 63 (37-89) |  |
Gender, n (%) | Â | Â | <0.001 |
 Male | 163 (34.4) | 120 (68.6) |  |
 Female | 311 (65.6) | 55 (31.4) |  |
Smoking, n (%) | Â | Â | <0.001 |
 Never | 222 (78.7) | 58 (49.6) |  |
 Ever | 60 (21.3) | 59 (50.4) |  |
 Unknown | 192 (100) | 58 (100) |  |
Tumor stage, n (%) | Â | Â | 0.04b |
 I | 34 (23.8) | 5 (6.8) |  |
 II | 6 (4.2) | 5 (6.8) |  |
 III | 19 (13.3) | 9 (12.4) |  |
 IV | 84 (58.7) | 54 (74.0) |  |
 Unknown | 331 (100) | 102 |  |
Histology, n (%) | Â | Â | <0.001c |
 Adenocarcinoma | 412 (98.6) | 123 (82.6) |  |
 Squamous cell carcinoma | 3 (0.7) | 23 (15.4) |  |
 Adenosquamous carcinoma | 2 (0.5) | 2 (1.3) |  |
 Sarcomatoid carcinoma | 1 (0.2) | 0 |  |
 Neuroendocrine neoplasms | 0 | 1 (0.7) |  |
 Unknown | 56 (100) | 26 |  |
Germline mutation, n (%) | Â | Â | 0.8 |
 Yes | 14 (3.0) | 6 (3.4) |  |
 No | 460 (97.0) | 169 (96.6) |  |
PD-L1 test, n (%) | Â | Â | 0.8 |
 TPS < 1% | 54 (63.5) | 34 (58.6) |  |
 TPS,1%-50% | 26 (30.6) | 19 (32.8) |  |
 TPS ≥ 50% | 5 (5.9) | 5 (8.6) |  |
 Unknown | 389 (100) | 117 (100) |  |
TMB | Â | Â | <0.001 |
 Mean (SD) | 3.5 (4.6) | 8.9 (9.2) |  |
 Median (min-max) | 1.9 (0-28.8) | 5.8 (0-68.0) |  |